Market Place
Sourcing Support
Vertex axes Verve gene editing pact amid shift in R&D priorities
28 Feb 2025 //
FIERCE BIOTECH
Verve moves forward with backup base editing therapy
08 May 2024 //
BIOPHARMADIVE
Verve Therapeutics First Patient Dosed In VERVE-102 Heart-2 Phase 1b Trial
07 May 2024 //
PRESS RELEASE
Verve Halts Trial for Lead Gene Editing Program Due to Safety Concerns
03 Apr 2024 //
BIOSPACE
Verve Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
PRESS RELEASE
Verve to Participate in Guggenheim Healthcare Talks 6th Annual Conference
01 Feb 2024 //
PRESS RELEASE
Verve raises $148M via public stock offering
29 Nov 2023 //
ENDPTS
Verve Therapeutics Announces Proposed Public Offering of Common Stock
28 Nov 2023 //
PRESS RELEASE
Verve Therapeutics Announces Pricing of Public Offering of Common Stock
28 Nov 2023 //
PRESS RELEASE
Verve shows base editing works in humans—and sees stock sink
13 Nov 2023 //
FIERCE BIOTECH
Verve Therapeutics Announces Interim Data for VERVE-101
12 Nov 2023 //
PRESS RELEASE
Verve Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Verve Therapeutics Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
PRESS RELEASE
Beam offloads Verve rights to Lilly for up to $600M
31 Oct 2023 //
FIERCE BIOTECH
Lilly beams up Verve gene therapy programs for $600M from deal-hungry Beam
31 Oct 2023 //
PRESS RELEASE
FDA frees Verve`s base editing therapy from clinical hold
23 Oct 2023 //
FIERCE BIOTECH
Verve to Present Data from the heart-1 Phase 1b Clinical Trial of VERVE-101
26 Sep 2023 //
PRESS RELEASE
Verve to Participate in the 2023 Cantor Global Healthcare Conference
21 Sep 2023 //
PRESS RELEASE
Verve Appointed Frederick T. Fiedorek, M.D., as Chief Medical Officer
18 Sep 2023 //
PRESS RELEASE
Intellia, Verve run trials abroad amid FDA’s ‘cautious’ approach to gene editing
17 Aug 2023 //
ENDPTS
Verve Therapeutics Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference
03 Aug 2023 //
PRESS RELEASE
Verve snags $60M from Lilly to tackle Lp(a) with one-time gene editing
16 Jun 2023 //
ENDPTS
Verve Establishes Collaboration with Lilly to Advance In Vivo Gene Editing Program
15 Jun 2023 //
PRESS RELEASE
Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
01 Jun 2023 //
PRESS RELEASE
Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes
23 May 2023 //
PRESS RELEASE
Verve names second PCSK9 candidate; Exscientia picks molecule for clinic
15 May 2023 //
ENDPTS
Verve stock spikes as Canaccord initiates with Buy (NASDAQ:VERV)
13 Apr 2023 //
SEEKING ALPHA
Further weakness as Verve Therapeutics drops 6.8% this week
05 Apr 2023 //
SIMPLYWALL
Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by UK MHRA
14 Feb 2023 //
GLOBENEWSWIRE
VERVE-101 Awarded Passport for Heterozygous Familial Hypercholesterolemia
14 Feb 2023 //
PRESS RELEASE
Do Verve`s gene edits pass down to patients` children? The FDA wants to know
06 Dec 2022 //
FIERCEBIOTECH
Verve Announces Results of Trial for Transurethral Renal Pelvic Denervation
16 Nov 2022 //
BUSINESSWIRE
Verve Therapeutics to Participate in Upcoming Investor Conferences
11 Nov 2022 //
PRESS RELEASE
Verve Provides Regulatory Update on VERVE-101 Investigational NDA
07 Nov 2022 //
PRESS RELEASE
FDA halts Verve plans to test gene editing therapy for heart disease in US
07 Nov 2022 //
BIOPHARMADIVE
Verve`s gene editing therapy placed on hold by FDA
07 Nov 2022 //
FIERCEBIOTECH
Verve Therapeutics Announces Publication of VERVE-101 Preclinical Data
31 Oct 2022 //
GLOBENEWSWIRE
Cathie Wood Loads Up $23M In Gene-Editing Company`s Shares As They Slump 10%
25 Sep 2022 //
BENZINGA
Verve Therapeutics to Participate in Upcoming Investor Conferences
22 Sep 2022 //
PRESS RELEASE
Verve Announces Clearance of CTA Application by the UK Medicines for VERVE-101
21 Sep 2022 //
PRESS RELEASE
Verve Therapeutics Inc Shares Close the Day 11.9% Lower - Daily Wrap
15 Sep 2022 //
NASDAQ
Verve Highlights Data Supporting Nomination of VERVE-201 ANGPTL3 at the ESC
22 Aug 2022 //
PRESS RELEASE
Verve Provides Corporate Updates and Reports Q2 2022 Financial Results
09 Aug 2022 //
PRESS RELEASE
Verve Therapeutics Announces Closing of Upsized Public Offering
25 Jul 2022 //
PRESS RELEASE
Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
21 Jul 2022 //
PRESS RELEASE
Verve Therapeutics Announces Proposed Public Offering of Common Stock
21 Jul 2022 //
PRESS RELEASE
Vertex, Verve team up to develop a gene editing drug for liver disease
20 Jul 2022 //
BIOPHARMADIVE
Verve begins human tests of first ‘base editor,’ aiming at heart disease
13 Jul 2022 //
STATNEWS
Revisiting Beam Therapeutics Among Collaborative Catalysts
10 Jul 2022 //
SEEKING ALPHA
Verve gets New Zealand clearance to test base editing therapy in the human body
10 May 2022 //
ENDPTS
Verve Tx Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene
04 Apr 2022 //
PRESS RELEASE
Verve to Participate in the Guggenheim Genomic and Rare Disease Conference
24 Mar 2022 //
PRESS RELEASE
Verve Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
14 Mar 2022 //
PRESS RELEASE
Another four IPOs complete busy week as biotech raise continues to match 2020`s
18 Jun 2021 //
ENDPTS
Gene editing biotech Verve to raise $267M in large IPO
17 Jun 2021 //
BIOPHARMADIVE
Rick Klausner`s crew of T cell specialists wraps $425M IPO
16 Jun 2021 //
ENDPTS
Gene editing biotech Verve Therapeutics sets terms for $201 million IPO
14 Jun 2021 //
FIERCEBIOTECH
Gene editing biotech Verve Therapeutics files for a $100 million IPO
28 May 2021 //
RENAISSANCECAPITAL
Verve Announces Nature Publication Highlighting its Use of PCSK9 and LDL-C
18 May 2021 //
BUSINESSWIRE
